<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195520</url>
  </required_header>
  <id_info>
    <org_study_id>0753T-101537</org_study_id>
    <nct_id>NCT00195520</nct_id>
  </id_info>
  <brief_title>Study Evaluating Totelle速 in Menopausal Symptoms and Sexual Function</brief_title>
  <official_title>An Open Assessment of the Effect of Low-Dose Totelle速 1 mg on Menopausal Symptoms, Sexual Function and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate the tolerability, bleeding patterns and acceptability of Totelle速 1mg
      administered to a population of Brazilian women in a continuous combined regime for hormone
      replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the tolerability, bleedeing patterns and acceptability of Totelle 1mg administered to a population of Brazilian women in a continuous combined regime for hormone replacement therapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of Totelle 1 mg on sexual function and quality of life.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Sleep Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Totelle速</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intact uterus

          -  Generally health postmenopausal women 45 to 60 years of age, inclusive

          -  Sexually active

          -  No hormone replacement therapy within the 90 days immediately prior to the screening
             evaluation.

        Exclusion Criteria:

          -  Known or suspect estrogen-dependent neoplasia

          -  Known hypersensitivity to estrogens, progestins, or other ingredients of Totelle

          -  Use of any estrogen, progestin, androgen containing medications or tibolone within 12
             weeks before screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jundiai</city>
        <state>Sao Paulo</state>
        <zip>13209-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04062-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <keyword>Menopause</keyword>
  <keyword>Sleep Disorder</keyword>
  <keyword>Hot Flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

